The US Food and Drug Administration has approved Eli Lilly’s (NYSE: LLY) once-weekly insulin Onswik for adults with type 2 diabetes, the company said on 24 September 2026.
It is the fourth global approval for the drug, insulin efsitora alfa-gobe, following clearances from regulators in the European Union, Mexico and Japan, according to HCPLive.
What the FDA approval covers
Onswik is designed to hold basal insulin levels steady over a full week, replacing the daily jabs most basal insulin users currently need. Lilly says the product could cut a patient’s basal injections from roughly 365 a year to 52, per HCPLive.
The clearance rests on the QWINT Phase 3 programme, which tested the drug in more than 3,400 adults with type 2 diabetes across four registration studies, Lilly said in its investor release. Each trial met its primary goal of reducing A1C by a margin non-inferior to insulin glargine U-100 or degludec U-100, according to PharmExec.
‘For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide, but delays in initiating treatment and the burden of daily injections can have a real impact on patients’ day-to-day experience managing type 2 diabetes,’ said Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, in a statement republished by BioSpace.
The approval was also reported independently by Reuters, which confirmed the FDA had cleared the once-weekly injection for type 2 diabetes patients.
Shares slipped, not rose, on approval day
Despite the regulatory win, Lilly stock did not rally on the news. Independent same-day pricing from Investing.com put LLY down about 1.6% in the regular session, the opposite of an earlier intraday pop some feeds had flagged.
The muted reaction fits a pattern seen elsewhere this year: investors appear to have priced in a widely expected fourth global approval well before Tuesday’s announcement, leaving little room for a fresh re-rating on the day itself.
Lilly’s diabetes franchise now competes directly with Novo Nordisk’s Awiqli, its own newly approved once-weekly insulin, intensifying a race between the two drugmakers to control the weekly-injection segment of the insulin market, according to pharmaphorum. The Onswik KwikPen is expected to launch in the US within months, in 500 units/mL and 1,000 units/mL formulations, per StockTitan.
The earnings backdrop
The approval lands against a run of sharply rising quarterly numbers at Lilly. Revenue climbed from $12.7bn in the first quarter of 2025 to $19.8bn in the first quarter of 2026, then to $22.97bn in the second quarter of 2026, according to SEC filings.
Net income has moved in step. Lilly reported $7.4bn in net income for the first quarter of 2026 and $7.1bn for the second quarter, up from $2.76bn and $5.66bn respectively a year earlier, the filings show. Diluted earnings per share reached $8.26 in the first quarter of 2026 before easing to $7.94 in the second, versus $3.06 and $6.29 in the corresponding 2025 quarters.
That growth trajectory has underpinned a broader re-rating story for the drugmaker, whose market value was reported to have topped $1 trillion earlier in September 2026 on obesity-drug and oncology momentum, according to ad-hoc-news.de.
Several Lilly directors and officers filed Form 4 disclosures with the SEC on 22 September 2026, two days before the Onswik announcement, including filings from Gabrielle Sulzberger, Juan R. Luciano, J. Erik Fyrwald and Ralph Alvarez, according to SEC EDGAR.
What happens next
Attention now turns to the US launch timeline for the Onswik KwikPen and to how quickly Lilly can convert a fourth global approval into prescriptions, as it battles Novo Nordisk for share of the once-weekly insulin category. Investors will also be watching Lilly’s next quarterly filing for signs of how the broader cardiometabolic portfolio, including Onswik, contributes to the revenue growth that has driven the stock’s re-rating this year.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
